Interventional Oncology Gains Momentum with Quantum Surgical Deal

 Medtech deal activity continues to move quickly, and the latest transaction highlights growing momentum in interventional oncology.

This week, Quantum Surgical acquired NeuWave Medical from Johnson & Johnson. Financial terms were not disclosed, but the strategic implications are clear. Quantum Surgical’s expertise in robotic assistance and navigation will now be combined with NeuWave’s Microwave Ablation System under a new organization called Precision IO Group.

The company will be led by Kurt Azarbarzin, a medtech executive whose background includes leadership roles at Verb Surgical, EndoQuest Robotics, and SurgiQuest.

For Johnson & Johnson, the transaction reflects continued efforts to streamline its portfolio and concentrate on higher-growth segments. For Quantum Surgical, the acquisition provides both a proven technology platform and direct access to a large installed base of leading cancer centers.

To understand why the deal matters, it helps to look at the underlying market data.

The Numbers Behind Interventional Oncology Growth

Johnson & Johnson acquired NeuWave Medical in 2016, but the company had recently planned to discontinue the business as part of a broader strategic refocusing around core divisions.

Despite that decision, the technology has established a meaningful clinical footprint. Since 2011, NeuWave systems have been used to treat more than 100,000 patients with challenging lung, kidney, and liver solid tumors.

Today, the serviceable market for these procedures is estimated at roughly 150,000 to 200,000 global cases annually. While that number may appear relatively modest, the epidemiology suggests a much larger long-term opportunity, with ~300,000+ new cases each year in the U.S.

Annual U.S. incidence, by tumor type:

  • Liver (HCC & Metastatic) ~42,000
  • Lung (NSCLC/Meta) ~229,000
  • Kidney (RCC) ~80,000

And while not a primary diagnosis, there are also roughly 280,000 patients with secondary bone metastases who need pain palliation, which can be addressed with NeuWave’s technology.

Historically, energy-based tumor ablation has often been considered a last-resort treatment. Technological advancements are enabling this to transition to a fourth pillar in cancer treatment, and a first-line treatment for any patients who qualify.

NeuWave is currently the market leader for microwave ablation in interventional oncology. The platform is estimated to account for roughly 60% to 70% of the U.S. market and is used in approximately 70% of leading cancer centers nationwide.

This installed base may be the most valuable part of the acquisition.

By acquiring NeuWave, Precision IO gains immediate access to these hospital accounts, which could accelerate adoption of Quantum Surgical’s Epione robotic-assisted platform.

Platform Control and Procedure Growth

As we’ve previously discussed, success and market share are dependent on controlling the approach. The Epione robot provides all of the advantages necessary to increase procedure growth.

The system enables physicians to reach difficult tumors with sub millimeter precision. For some patients, that level of accuracy determines whether treatment is possible at all.

Robotic needle placement also helps standardize procedures. Hospitals and ambulatory surgery centers can reduce variability between operators, allowing less experienced physicians to perform cases more consistently.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/interventional-oncology-gains-momentum-with-quantum-surgical-deal

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more